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Abstract
Objectives:  In the last several decades, the knowledge of the cystic neoplasms has
enlarged and the  management  has  changed.  The wide adoption in  the  diagnostic
procedures  of  routine  and  advanced  imaging  has  become  the  cornerstone  of  the
diagnosis.
Methods: Pancreatic cystic tumors comprise neoplasms with a wide range of malignant
potential. The most common include serous cystic neoplasm, mucinous cystic
neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), solid
pseudopapillary neoplasms (SPPNs), and cystic pancreatic endocrine neoplasms
(CPENs). Other cystic lesions are acute postnecrotic pseudocysts and chronic pseudo‐
cysts. Finally, the indeterminate cystic lesions have been presented.
Results: The epidemiology, pathological features, imaging characteristics, clinical
evolution, and therapeutic choices of the most frequent lesions as well as less frequent
forms are described. This study can be completed with the presentation of some cases
of cystic pancreatic neoplasms treated in our service.
Conclusion: The improvement of imaging, endoscopic modalities, and cyst fluid studies
allows now accurate and reliable diagnosis of pancreatic cystic lesions. Moreover, the
enlarged knowledge of valuable pathological studies established the potential for
malignant transformation of these lesions identifying higher‐risk neoplasms. Finally,
the management options should be based on the assessment of each type of cystic
neoplasms and the distinction of pancreatic cystic neoplasms (PCNs) from other cystic
lesions.
Keywords: cystic pancreatic lesions, pancreas, pseudocysts, pancreatitis, indetermi‐
nate pancreatic cystic lesions
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1. Introduction
Cystic lesions of the pancreas are less frequent in relation to solid neoplasies. These lesions
have attracted new and great interest. In the last several decades, the knowledge of the cystic
neoplasms has enlarged and the management has changed dramatically. The wide adoption
in the diagnostic procedures of routine and advanced imaging such as ultrasonography (US),
computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance chol‐
angiopancreatography (MRCP), and endoscopic ultrasound (EUS) has become the cornerstone
of the diagnosis.
EUS‐guided fine needle aspiration (FNA) can allow the assessment of tumor markers,
chemistries, cytology, and DNA analysis. Also pathological study has played a very important
role.
2. Classifications and epidemiology
The recent WHO classification 2010 of all pancreatic tumors is more extensively used. This
classification encompasses epithelial tumors (benign, premalignant lesions, malignant lesions,
and neuroendocrine neoplasms), mesenchymal tumors, lymphomas, and secondary tumors
[1].
Based on pathological, clinical and radiologic assessments, some not recent but valuable [2],
several classifications of cystic pancreatic neoplasms and lesions have been proposed. We
believe interesting to note the proposed classification that fully includes all cystic lesions of
the pancreas [3]. This classification includes the following cystic lesions: neoplastic epithelial
(benign, borderline, and malignant), non‐neoplastic epithelial, neoplastic non‐epithelial (very
rare), and non‐epithelial non‐neoplastic (very rare).
The frequency of each cystic lesions is not defined with precision, may be for observers
diversity (surgeons, radiologists, and pathologists) and for the assessment of different
developmental stages of lesions.
Pancreatic cystic tumors comprise a variety of neoplasms with a wide range of malignant
potential: benign, borderline, and malignant. The classification proposed by Kosmahl encom‐
passes the majority of the recently now described lesions (Table 1).
Many cystic neoplasms listed in the classifications are infrequent or rare pathological varieties,
with minimal and not evident clinical characterization [4]. The simplified classification can be
proposed that comprises two groups of lesions:
• Non‐mucinous cystic lesions: inflammatory pseudocysts without a true epithelial lining (in
the setting of acute and chronic pancreatitis), serous cystic neoplasms (SCNs), solid
pseudopapillary neoplasms (SPPNs), and cystic pancreatic endocrine neoplasms (CPENs).
• Mucinous cystic lesions (epithelial lining produces mucinous cyst fluid): intraductal
papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs).
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Cystic epithelial tumors Non‐neoplastic epithelial cysts
Benign Congenital cyst
Intraductal papillary mucinous adenoma Lymphoepithelial cyst
Mucinous cystic adenoma Retention cyst
Serous microcystic adenoma
Serous oligocystic ill‐demarcated adenoma
von Hippel–Lindau‐associated cystic neoplasm
Benign cystic neuroendocrine tumors
Acinar cell cystadenoma
Cystic teratoma (dermoid cyst)
Borderline Non‐neoplastic non‐epithelial cysts
Intraductal papillary mucinous neoplasm borderline Pancreatitis‐associated pseudocysts
Parasitic cysts
Mucinous cystic neoplasm borderline
Solid pseudopapillary neoplasm
Malignant
Intraductal papillary mucinous carcinoma
Mucinous cystic carcinoma
Ductal cystic adenocarcinoma
Serous cystadenocarcinoma
Cystic non‐epithelial tumors
Lymphangioma
Sarcomas
Table 1. Classification of cystic neoplasms and lesions of pancreas [3].
This classification highlights as criterion of differentiation the presence of mucinous epitheli‐
um characterized by malignant potential.
Another criterion of classification of cystic lesions of pancreas is based on the epithelium lining
of the cyst (Table 2).
In summary, the most common neoplasms include: serous cystic neoplasms (SCNs)/serous
cystadenoma, mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms
(IPMNs), solid pseudopapillary neoplasms (SPPNs), and cystic pancreatic endocrine neo‐
plasms (CPENs). There are others rare or very rare tumors: acinar cells cystadenoma, cysta‐
denocarcinoma, cystic teratoma (dermoid cyst), and cystic pancreatoblastoma. Pancreatic
cystic tumors are rare and less frequent than others pancreatic tumors. Image‐based studies
show prevalence of pancreatic cystic lesions ranging from 1.2 to 19% [6, 7].
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No lining → Pseudocysts (pancreatitis associated)
Lining
Mucinous epithelium
MCNs
IPMNs
Serous epithelium
SCNs
VHL‐associated pancreatic cysts
Squamous epithelium
Lymphoepithelial cysts
Acinar cells
Acinar cell cystadenocarcinomas
Endothelial lined cysts
Lymphangiomas
Degenerative necrotic changes in a neoplasm
SPPNs
CPENs
Cystic ductal adenocarcinomas
Table 2. Classification of cystic lesions of the pancreas [5].
In the autopsy series, the prevalence reaches 24% [8]. All cystic tumors of the pancreas reach
about 10–15% of all cystic pancreatic lesions [7]. The exact prevalence of cystic pancreatic
tumors is not defined. Autopsy study shows a prevalence of 24.3%; however, imaging studies
have found the prevalence of 1.2–2.4%. On the other hand, pseudocystic lesions reach 90% of
all pancreatic cystic lesions but only 45% of these patients had previous pancreatitis [6]. The
economic impact that is necessary to follow these patients by imaging studies should be
evaluated.
The epidemiologic and demographic features are different in the several types of cystic tumors,
and they will be presented in specific sections.
3. Diagnostic perspectives and management options
The current use of imaging modalities has allowed some important results in the nosographic
study: certain distinction between postnecrotic acute or chronic pseudocysts and cystic tumors;
among the cystic neoplasms, the identification of clinical pathological features that allow
recognizing some kinds of cystic tumors with several perspective of neoplastic evolution.
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Cystic and intraductal mucinous neoplasms are pancreatic tumors of ductal origin and are
characterized by cysts lined by mucinous epithelium.
Cystic tumors of the pancreas have the characteristic of precursor: they may be associated with
or progress to invasive carcinoma. They are the preinvasive neoplasms, as the pancreatic
intraepithelial neoplasms, but these tumors form clinically detectable masses, usually before
that they become invasive, as the gastrointestinal adenoma. From these data, we take the
therapeutic decision. A rough and summary monitoring of this setting clearly shows that cystic
lesions are becoming increasingly more common, particularly among resection specimens. The
reasons for this increase in frequency are various: important improvement in imaging
techniques allows increased detention of clinically silent neoplasms; the majority of the cystic
tumors are surgically removable because they are non‐infiltrative in their evolution, and finally
great decrease in postoperative complications and mortality rate of pancreatic surgery. The
increased imaging and pathological studies and confirmation of all pancreatic cystic lesions
result in better knowledge of these lesions.
A rough estimate of relative frequency of the pancreatic cystic lesions from the published data
in the literature has been reported [5, 9]: pseudocysts (pancreatitis associated), 30%; IPMNs,
20%; MCNs, 10%; SCNs, 20%; acinar cell cystadenocarcinomas, lymphoepithelial cysts and
lymphangiomas, <5%; SPPNs, <5%; cystic ductal adenomas, <5%; CPENs and metastasis, <5%.
The more simple classification of pancreatic cystic lesions subdivides two main classes: non‐
neoplastic cysts with pseudocysts non‐lining and simple or congenital cysts, retention cysts
that reach 80% of cases; neoplastic cysts or lining lesions that set up 20% of cases and can be
defined pancreatic cystic neoplasms (PCNs) [7]. The main problem in the management of these
lesions is the sure distinction between non‐neoplastic cysts (pseudocysts, retention, and simple
cysts) and pancreatic cystic neoplasms. Moreover, in the latter group, we need to distinguish
non‐mucinous from mucinous cysts that are considered being premalignant lesions. The
therapeutic choices can be very different from simple follow‐up to surgical resection. The WHO
[1, 10] histological classification of tumors of exocrine pancreas and classification of pancreatic
cystic lesions, integrated and updated by Kosmahl et al. [3] should be valuable references in
the development of this subject. The specific epidemiology, histological features, imaging
characteristics, clinical evolution, and therapeutic choices of the most frequent lesions as well
as rare forms are described in each specific section.
4. Serous cystic neoplasms (SCNs)
SCNs can be divided into serous cystadenoma and serous cystadenocarcinoma. Serous
cystadenoma is a benign neoplasm consisting of uniform glycogen‐rich epithelial cells that
give rise innumerable small cysts containing serous fluid. These lesions arise from centroacinar
cell‐intercalated duct system [11, 12], producing MUC6.
Histological and immunohistochemical data characterize the morphology and pathological
evolution of serous cystadenoma. The cells lining the small cysts have clear cytoplasm with
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well‐defined border and round uniform nuclei. They are negative for mucin stains; in these,
lesions are not present the molecular genetic alterations, specific of mucinous‐type ductal
pancreatic neoplasia such as mutation in the K‐ras, SMADH4/DPC4, TP53, and p16 genes [13].
In the pathogenesis of serous cystadenomas, the alterations of von Hippel‐Lindau (VHL) gene
have been demonstrated in 40% of cases [3]; therefore, serous cystadenomas are associated
with von Hippel‐Lindau syndrome, an autosomal dominant disorder, characterized by
hemangioblastoma of central nervous system and retina, renal cysts and neoplasms, and
phaeochromocytomas. The pancreatic cystic lesions in VHL syndrome usually develop earlier
than central nervous system lesions.
The relative frequency of serous lesions into cystic pancreatic neoplasms ranges from 20 to
30%.
The SCNs occur predominantly in female patients (female/male ratio 3:1) of sixth–seventh
decade. Almost 70% of SCNs occur in the body or tail of the pancreas and 30–40% of the patients
are asymptomatic, and the lesions are detected incidentally. Symptomatic patients can present
some trouble caused by size of the neoplasm such as abdominal pain, discomfort, malaise,
anorexia, or objective signs as palpable mass, jaundice, and weight loss.
On imaging studies (CT or MRI), SCNs may present with two main morphologies: the more
frequent, classic microcystic appearance and the less common oligocystic appearance.
Microcystic‐type lesions present multiple small cysts, in one‐third of cases with a central
fibrous scar and calcification creating a sponge‐like appearance, which can be considered
pathognomonic. The size of the mass, much variable, ranges from few centimeters to 20–25 
cm.
There are rare cases of oligocystic‐type pattern (megacystic and macrocystic). This type consists
of fewer and larger loculi, with lobulated contour without wall enhancement and usually is
located in the pancreatic head [14]. The epithelial lining of these cysts may become denuded
and can be difficult to distinguish from mucinous neoplasms. In this case, it can be useful to
identify the characteristic glycogen‐rich clear cells [15].
On EUS, the SCNs show multiple, small, anechoic cysts and thin septations. There is a vascular
network on cyst wall. The aspirated cyst‐fluid from EUS‐FNA is low in CEA concentration,
and the result of cytology is poor.
For SCNs, the risk of malignancy is <1%. SCNs with certain clinical diagnosis, little in size,
from 2–2.5 to 4–5 cm, asymptomatic can be observed. The criteria of the control are based on
increase of the size lesion and increase of the tumor markers (CEA). Beside the benign serous
cystadenomas that are the majority of cases, there are also few malignant lesions, serous
cystadenocarcinomas [16]. The structural histological findings are overlappable between
serous cystadenoma and cystadenocarcinoma, and often only the metastatic potential should
distinguish the malignant variants.
In the SCNs, the certainty of the preoperative diagnosis is most important for the therapeutic
choice between non‐operative management with follow‐up and surgical treatment. Three
Challenges in Pancreatic Pathology98
criteria should be evaluated for surgery: likelihood of malignant evolution, symptoms caused
by increase of the size of the tumor, and age of the patient.
Malignant SCNs constitute <3% of all SCNs [17], but within these cases, there are also serous
cystadenocarcinomas not as evolution of benign tumors. Therefore, the global risk of malig‐
nancy of SCNs is <1% [18, 19].
A lot of the patients are asymptomatic at the diagnosis (incidental diagnosis). The likelihood
of symptoms increases with the size of tumor. In fact, 22% of the patients is symptomatic with
tumor <4 cm in diameter, but for tumor more than 4 cm, 77% of the patients becomes symp‐
tomatic [19].
The average age at the diagnosis frequently is 65 years or more.
The choice of treatment of SCNs can be summarized. We can consider several cases:
• old patients (>65 years), asymptomatic, size tumor <4 cm with pathognomonic imaging
appearance should be observed;
• young patients (<65 years), asymptomatic, size tumor <4 cm with pathognomonic imaging
appearance also should be observed;
• patients asymptomatic, size tumor >4 cm with pathognomonic imaging appearance could
be observed (but the surgery can be discussed);
• patients symptomatic, size tumor >4 cm with pathognomonic imaging appearance should
be proposed for surgery;
• cases with not complete diagnostic appearance or uncertain diagnosis should be proposed
for surgical treatment.
In summary, surgical indications for SCNs with certain diagnosis (imaging, fluid cyst evalua‐
tion, etc.) are based on serious symptoms, great size tumors, or great increase of the size tumor
in patient diagnosed and followed over time and increase of tumor marker (CEA) in fluid cyst
[20].
5. Mucinous cystic neoplasms (MCNs)
These are the most frequent cystic pancreatic neoplasms. They amount for 20–40% of all cystic
tumors with the prevalence of 25–30% for mucinous cystadenoma and 15% for mucinous
cystadenocarcinoma.
There are two types of MCNs, both not communicate with the pancreatic duct. The cysts are
lined by columnar, mucin‐producing ductal epithelium and sometimes papillary epithelium.
In the first type, ovarian‐type stroma is located under the epithelial layer; the ovarian‐type
stroma is positive to estrogen and progesterone receptors [6]. Ectopic ovarian stroma can be
included in the pancreas during embryogenesis and this can cause, by releasing hormones, the
proliferation of epithelium and then the cystic neoplasm. This hypothesis that connects the
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stromal component of MCNs and ovarian tissue should be supported by morphological
resemblance. This type is present almost exclusively in women of fifth–sixth decade and
predominantly is located in body and tail of pancreas.
There is another type of MCNs, more common, without ovarian stroma that can be located
anywhere in the pancreas and occurs in both sexes. The malignant potential is very high in
MCNs based on the possible evolution of mucinous transitional epithelium. Consequently,
MCNs may be classified based on the degree of dysplasia: MCNs with low‐intermediate grade
dysplasia, with high‐grade dysplasia, and finally with associated invasive carcinoma [14].
Histological heterogeneity of MCNs is in evidence with coexistence of benign appearance and
malignant epithelia. Malignancy, in situ or invasive, is found in 35–45% of cases [21].
The macroscopic appearance of MCNs is cystic mass, unilocular or multilocular, containing
thick mucine or sometimes mixed with hemorrhagic materials. The cystic wall is well defined,
fibrous, and sometimes (10%) calcified.
Clinical appearance in the symptomatic patients presents abdominal pain, palpable mass,
anorexia, fatigue, weight loss, and in some cases pancreatitis. The results of routine laboratory
examinations are generally non‐specific. One‐third of patient can be asymptomatic [22].
Imaging examinations (CT and MRI) of MCNs show large cysts with septae and in some cases
peripheral thin calcification of the walls. In some experiences, the presence of peripheral
calcification, wall thickening, and thick septation has been highlighted as important for
malignant evolution of MCNs [23]. Overlappable data can be detected by EUS: mass formed
from fluid‐filled cysts with thin walls, septae, and diameter 1–2 cm without duct communica‐
tion. Malignancy suspicious can be based on wall thickening, irregularity, intracystic solid
mass, and increased size of all lesion.
EUS‐FNA can allow the evaluation of fluid content of cysts: CEA levels are high and can be
useful in the diagnosis [6]. Pathological and evolutionary characteristic of MCNs affect
treatment decisions. Malignant potential of these neoplasms is the cornerstone of the therapy.
Relevant is the increase in the frequency of K‐ras and p53 mutations as in sequence adenoma–
carcinoma of colon cancer. Consequently, there is high likelihood of evolution into cancer if
untreated. In fact, there is age difference of 10 years longer between patients with cystadeno‐
carcinoma and patients with cystadenoma [24, 25]. Based on the pathological characteristics
of histologic heterogeneity, extensive histologic sampling is necessary for certainty of diagnosis
(from adenoma to carcinoma). The current and unanimous guidelines propose the surgical
treatment for all MCNs. The contraindications for intervention are related to the patient's
conditions. The pancreatic resection is connected with the location of lesion: head, body, and
tail. Duodenopancreatectomy, middle pancreatectomy, and distal pancreatectomy with or
without splenectomy should be performed. Less extensive resections, such as enucleations are
not recommended also because usually followed by high complications rate. Laparoscopic
approaches are becoming more common and fully justified.
Cure rate of surgical resection for non‐invasive MCNs (carcinoma in situ) is 100%. The 5‐year
survival rate for resected patients with invasive lesions is 40–50%; whereas the 2‐year survival
rate is 60–70%. Surveillance after surgery in these patients is required.
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6. Intraductal papillary mucinous neoplasms (IPMNs)
The incidence of IPMNs is not well defined. In the recent years, their detection is increased
based on the technical improvement of imaging examinations and the better knowledge of
pathological features. Some data from the literature report that incidence range from 20 to 50%
of all pancreatic cystic neoplasms [6, 26, 27]. Tumor arises from epithelium of the main
pancreatic duct or its side branches. The lesions are lined by the intraductal proliferations of
ductal columnar mucin‐secreting epithelium with papillary projections that cause obstruction
and dilatation of the duct. Tumors localized in the main pancreatic duct can spread in the rest
of the duct. Men and women are equally affected. The neoplasm can be located anywhere in
the pancreas. The most frequent localization of lesion is in the head of the gland and in 20–
30% of cases can be multifocal. In 5–10% of cases, the pancreas can be diffusely interested [26,
27]. There are two varieties of this neoplasm, following its localization: main duct type (MD‐
IPMNs), most frequent (57–92%), and side branches type (BD‐IPMNs), localized in the side
branches of ductal system, less frequent (6–46%) [28]. In the combined type of IPMNs, main
and branch ducts are both involved. IPMNs encompass epithelial changes from adenoma as
premalignant lesions to carcinoma in situ, based on the progression of dysplasia, and finally
invasive carcinoma. The degree of dysplasia allows the classification of IPMNs: IPMNs with
low‐ or intermediate‐grade dysplasia, IPMNs with high grade, and IPMNs with invasive
carcinoma.
The characteristic behavior of IPMNs progresses toward malignancy. There is, in the observa‐
tional studies, an age difference, 6 years longer, between patients with malignant tumors and
patients with mucinous adenoma [29]. The communication with pancreatic duct system is
characteristic. According to histological features (architecture and cytology), four types of
IPMNs, such as gastric, intestinal, pancreatobiliary, and oncocystic, have been described.
Gastric‐type epithelium is frequent in side branches type with better prognosis (malignant
potential 28%); intestinal‐type and pancreatobiliary‐type epithelia are more frequent in main
duct type with bad prognosis (malignant potential 60%) [30]. Several patients can be sympto‐
matic with non‐specific symptoms. Clinical appearances can be usually abdominal discomfort
or pain, malaise, nausea, and vomiting. Frequently, first clinical appearance is acute pancrea‐
titis generally with benign evolution, due to mucous obstruction of the pancreatic ducts. Acute
pancreatitis can be recurrent in 20% of cases. In most cases, IPMNs are asymptomatic. IPMNs
with invasive carcinoma should be associated with more evident clinical data such as weight
loss, jaundice, and diabetes.
IPMNs usually are diagnosed in elderly (sixth decade). Because high likelihood of malignant
evolution of these lesions, there is an age difference, 6 years longer, between patients with
malignant or benign lesions [29]. The results of blood examinations, as liver function tests,
lipase, amylase, serum CA 19‐9, and CEA, and routine tests are non‐specific for these pancreatic
cystic neoplasms.
Imaging examinations are decisive for diagnosis. They can be less invasive such as US, CT,
MRI, and more invasive such as EUS, endoscopic retrograde cholangiopancreatography
(ERCP).
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Transabdominal US has limited diagnostic role. This examination can show dilatation of the
main duct with cystic images around the ducts and thick mucinous content. Sometimes, US
can detect the duct communications. CT and MRI are currently employed in the diagnostic
assessment of IPMNs. These examinations can detect morphological features of the lesions:
size and location, calcification, pancreatic duct dilatation, appearance of the cysts with septae,
and thickening of wall. These morphological appearance detected by imaging examinations
can identify IPMNs excluding other cystic pancreatic lesions and can distinguish the MD‐
IPMNs from BD‐IPMNs. MRI and CT can also demonstrate the communication between the
duct and cyst.
In the past years, endoscopic retrograde cholangiopancreatography (ERCP) was crucial
imaging examination in the diagnosis of IPMNs. ERCP may detect dilated main pancreatic
duct with mucinous filling and/or intraductal proliferations. These features are characteristic
of MD‐IPMNs. Whereas in the BD‐IPMNs, the examination shows cystic lesions due to
dilatation of affected branch ducts that communicate with main pancreatic duct.
In some cases, the imaging studies show a dilated pancreatic duct but not the intraductal tumor.
Moreover, the dilation can be proximal and distal to the tumor, because of overproduction of
mucous. Classically, the endoscopic observation of open Vater's papilla and mucin extrusion
has been reported.
Unfortunately, ERCP is invasive procedure and its diagnostic use has been limited. In the recent
years, EUS plays an important role in the diagnostic program of pancreatic diseases. EUS
should be useful in the differentiation of types of IPMNs. EUS findings in MD‐IPMNs can be
a characteristic of morphological changes of these lesions such as various extension and degree
of duct dilatation and, in some cases, the presence of intraductal tumor. The recurrent acute
pancreatitis can show several parenchymal damages such as edema and enlargement of the
gland or signs of parenchymal atrophy. Characteristics of BD‐IPMNs are the lesions formed
by multiple little cysts (few millimeters) with internal septation, mucous, wall nodule, or
thickening, intracystic papillary projections. The Wirsung's duct should be moderately
dilated [31].
Based on EUS findings, some criteria of malignancy in IPMNs were defined: great dilatation
(>10 mm) of the main pancreatic duct and evident, large intraductal tumor (>10 mm) in MD‐
IPMNs; large cystic lesions (>40 mm) with thick, irregular septation, wall thickening, mural
nodule in BD‐IPMNs. We can also add to these criteria of malignancy the vascular invasion
and lymph node metastases. The accuracy of EUS malignancy criteria ranges from 40 to 90%
[32, 33]. Fine needle aspiration biopsy (FNAB) during EUS allows taking samples for bio‐
chemical, cytological, and DNA analyses. The first macroscopic finding is the mucinous fluid
characteristic of MCNs and IPMNs. High concentration of CEA should be characteristic of
mucinous lesions, such as high level of amylase because duct system communication. Brugge
has emphasized the cutoff CEA level for differentiating mucinous from non‐mucinous
pancreatic cystic lesions: the CEA level of 192 ng/ml has the sensitivity of 73% and specificity
of 84% [34]. Unfortunately, this analysis not distinguish MCNs from IPMNs and benign from
malignant lesions. Cytological study should be useful for the diagnosis of mucinous lesions
with the presence of epithelial cells (different from glycogen‐rich clear cells of serous cysta‐
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denoma). Moreover, the presence of high‐grade cytological atypia relevant to malignancy can
be detected [35]. DNA analysis of pancreatic cyst fluid shows K‐ras mutation, characteristic
for mucinous lesions, and GNAS mutation more present in IPMNs. The latter can differentiate
IPMNs from MCNs [36].
The planned interventions for treatment of IPMNs are duodenopancreatectomy or distal/
middle pancreatectomy based on location of lesions. We need to take into account that the
tumors localized in the main pancreatic duct can spread in the rest of the duct. Consequently,
the surgical planification can have changes with possible extension of pancreatic resection to
allow negative or low‐grade dysplasia at surgical margins. In fact, intraoperative frozen section
diagnosis of the transection margin shows positive results in 20–50% of cases [28]. Surgical
indications for IPMNs are based on risk of malignancy that is different for MD‐IPMNs and for
BD‐IPMNs. The frequency of malignant potential in MD‐IPMNs is 61.6% and the frequency
of invasive IPMNs is 43.1% [32]. The malignant potential in BD‐IPMNs reaches 28% and the
frequency of the invasive lesions is 18%. Therefore, the indication for pancreatic resection is
justified and recommended in the majority of the patients with MD‐IPMNs by international
consensus guidelines [32]. On the contrary, surgical indications in the patients with BD‐IPMNs
are more debatable. IPMNs, with some not negligible differences between main duct type and
branch duct type, encompass epithelial changes from adenoma, carcinoma in situ, and invasive
carcinoma. The lesions benign at the beginning progress toward malignancy. This character‐
istic of biological evolutivity makes difficult and complex the surgical indications or the timing
of intervention after a possible observation period. Beside the positive and specific diagnosis
of each type of cystic pancreatic neoplasm as IPMNs or MCNs, SCNs are crucial for the next
diagnostic step, recognizing the malignancy of the neoplasm. In the difficult diagnosis of
IPMN, the criteria based on CT imaging suggested by international consensus guidelines
should be useful [32]. These criteria have been subdivided as “high‐risk stigmata” and
“worrisome features.” The first are obstructive jaundice in a patient with cystic lesion of the
head of the pancreas, enhancing solid component within cyst, main pancreatic duct size of 5–
9 mm, or main pancreatic duct >10 mm in size. The “worrisome features” are cyst size >3 cm,
thickened/enhancing cyst walls, non‐enhancing mural nodule, and lymphadenopathy [32].
Ablation therapies of cystic neoplasms have been proposed: EUS‐guided injection of cytotoxic
agents (e.g., paclitaxel, ethanol) and radiofrequency ablation. These procedures are not widely
employed and their results are not defined and can be evaluated with difficulty, also because
these ablation therapies have been used for various PCNs [37–39]. The results of surgical
treatment for non‐invasive disease are very positive with 5‐year overall survival of 100%; for
invasive disease, 5‐year overall survival drops to 50–60% [28]. Recurrence rate of IPMNs can
be evaluated after surgical resection. The mean recurrence rate is 15% in the remnant pancreas
(ranges from 7 to 30%). The recurrence of IPMNs as invasive disease ranges from 3.4 to 44%
[40, 41]. The differential diagnosis between IPMNs and chronic pancreatitis can be difficult in
some cases. Usually, alcohol abuse is frequent in chronic pancreatitis. Several clinical and
morphological features are common to both diseases: main duct and branch duct dilatation,
intracystic and intraductal calcifications, and recurrent episodes of pancreatitis. Moderate and
segmental dilatation of main pancreatic duct with intraductal lithiasic obstruction, moderate
dilatation of the branch ducts communicating with main duct, and finally the widespread of
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the pancreatic ductal system are characteristic of chronic pancreatitis. On the contrary,
segmental and marked dilatations of the branch ducts with little calcifications are character‐
istics of IPMNs.
7. Solid pseudopapillary neoplasms (SPPNs)
SPPNs represent 9% of all cystic pancreatic tumors and have the major incidence in young
female patients (second–third decade). SPPNs are a neoplasm of unknown, not well‐defined
origin: in fact, in the past, various descriptive names were employed. The macroscopic
appearances of SPPNs are large solid masses (8–10 cm in size) and well encapsulated, and often
the cut section shows areas of hemorrhage, cystic degeneration, and solid areas. The micro‐
scopic features are polygonal epithelioid cells that form solid pseudopapillary structures
alternated hemorrhagic necrotic pseudocyst. There is also evident extensive vascular network,
often with infiltrative growth pattern. Alterations in the antigen‐presenting cell/beta‐catenin
pathway [42] and vimentine positive can be present. The histologic picture may resemble
closely to pancreatic endocrine neoplasms (PEN) but chromogranin is negative. In some cases,
histologic criteria of malignancy such as high nuclear grade, venous invasion, and atypical
cells may be observed; the metastatic spread is possible (10–15% of cases). SPPNs can be located
in all side of the pancreas. Clinical appearances are abdominal pain, palpable mass, nausea/
vomiting, jaundice, and weight loss. The imaging examinations (CT, MRI, and EUS) show a
solid and cystic masses with a well‐defined and thick capsule with sometimes peripheral
calcifications without septations. EUS‐FNA provides little information. SPPNs can be consid‐
ered lesions with low malignity and rare occurrence of metastasis, usually hepatic (10–15%).
The recommended treatment is surgery and the complete resection is often possible (94%); the
cure rate reaches 85–95% of patients [6, 44]. The pancreatic resection is based on the location
of neoplasm in the gland [43, 44].
8. Cystic pancreatic endocrine neoplasms (CPENs)
CPENs encompass 8% of all pancreatic cystic tumors and about 15% of pancreatic neuroen‐
docrine tumors [45, 46]. The majority of CPENs are non‐functioning and asymptomatic. These
neoplasms usually are diagnosed in elderly patients (sixth–seventh decades) without sex
prevalence. They can be associated with multiple endocrine neoplasia types. The diagnosis,
generally incidental, is based on imaging examinations (US, MRI, and CT). Cystic mass is
usually with hypervascular rim, and in several cases, there is septation or a solid component
[45]. The lesions are generally well circumscribed with regular wall around areas of cystic
degeneration.
EUS‐guided FNA can reveal low levels of CEA. Immunohistochemical staining for chromog‐
ranine and synaptophysin is present. Malignant potential of CPENs is not clearly defined
because it is difficult to detect malignancy on biopsy. The lesions are considered premalignant,
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and surgical treatment is indicated especially for lesions plus than 2 cm in size. The resective
surgery presents excellent results with very long survival (plus than 85% of patient treated)
[46]. Observational strategy has been proposed [47] for CPENs based on the similar experience
with non‐functioning pancreatic endocrine neoplasms (PENs) [48]. The results of non‐
operative choice are not defined.
9. Acute postnecrotic pseudocysts
Pancreatic pseudocysts are inflammatory lesions. They are evolutions and complications of
chronic and acute pancreatitis. The etiologies of pancreatitis are various: alcoholic, biliary, or
traumatic. The pseudocysts represent about 80% of all cystic lesions of the pancreas. The
pseudocyst wall has no epithelial lining unlike the true cysts [49]. Histologically, the pseudo‐
cyst wall consists of fibrosis and inflammatory tissue. Moderate and severe acute pancreatitis
are characterized by fluid necrotic collections in or near the pancreas at the beginning without
wall. With the flogistic evolution, the fluid necrotic collections are surrounded by granulation
and fibrous tissue [50]. Acute postnecrotic pseudocysts are the final evolution of necrotizing
pancreatic gatherings, characterized by complete separation of the tissues, with liquid content
and a fibrous wall [51]. The incidence of acute pseudocysts is low, at 5–16%. Several clinical
imaging and chemistries features can be useful for differential diagnosis between pseudocysts
and cystic pancreatic tumors. In the history, there is usually previous pancreatitis; the cystic
walls are regular and thin, without calcification: in the 65–70% of cases, there is the commu‐
nication with Wirsung's duct; in the intracystic fluid, CEA, CA19‐9, and mucous cells, on the
contrary increased amylase and lipase, are absent. The evolution of a lesion with a fibrous wall
and the formation of a pseudocyst can be completed in several weeks and in some cases in a
longer period (12–16 weeks). Small cysts (<5–6 cm) can develop for many months without
clinical appearance. In some cases, spontaneous improvement until the resolution of the
pseudocysts can occur [52].
Diagnosis of acute postnecrotic pseudocysts is greatly facilitated by the history of previous
episodes of acute pancreatitis. The imaging examinations (transabdominal US, CT, MRI, and
MRCP) are crucial for positive diagnosis (sensitivity of CT is very high 90–100%) [49]. Char‐
acteristic picture on CT is roundish cyst, fluid filled, without septations, and surrounded by a
thick wall around the pancreas. EUS can be used for further evaluation but usually do not add
other information on CT. EUS‐guided FNA and cyst fluid analysis can demonstrate high
amylase concentration.
The size of pseudocysts (plus than 6–7 cm) and the clinical presentation and evolution (lesions
symptomatic and/or persistent over many months) can direct the treatment [53].
The choice of therapeutic procedure should be based on the very frequent connection of the
acute pseudocysts with pancreatic ducts [53]. The percutaneous US/CT‐guided drainage is
usually complicated by pancreatic fistula with persistent leakage from the drain, infection, and
repeated changes of the drain [53, 54]. Therefore, the intervention of choice must provide
persistent drainage of pancreatic secretion by a cystodigestive anastomosis or fistulas [53].
Management of Pancreatic Cystic Lesions
http://dx.doi.org/10.5772/65117
105
Another pathological characteristic of acute pseudocysts is the close connections with various
adjacent intestinal organs (stomach, duodenum, and small intestine) according to the ana‐
tomical site where the pseudocyst develops [53].
Drainage of the pseudocysts by endoscopic technique has been proposed [55, 56]: this is
performed by creating a small opening between the cyst and the stomach. The disadvantage
of this techniques is incomplete drainage with recurrence of pseudocysts and infections
because the communication can be small and in site not declive [53, 57]. The surgical cystodi‐
gestive anastomosis can employ the more adjacent intestinal organ (stomach or duodenum or
small intestine) and can perform cystogastrostomy or cystojejunostomy or cystoduodenosto‐
my [52, 53].
For cysts located in the body or tail of pancreas, the cystojejunostomy or cystogastrostomy is
performed depending on the development of the cyst above or under the mesocolon. For
pseudocysts located on the head of the pancreas, cystoduodenostomy is usually performed.
The same surgical procedures can be performed with a laparoscopic approach with the
advantage of the minimal invasiveness [53].
10. Chronic pseudocysts
In the chronic pancreatitis parenchymal fibrosis and ducts, dilatation can cause chronic
pseudocysts [53]. Chronic pancreatitis encompasses various complications. Most frequent are
pseudocyst formation, mechanical obstruction of the duodenum, or common bile duct.
Pseudocysts occur in about 10% of patients with chronic pancreatitis. There are great patho‐
logical differences from acute and chronic pseudocysts. The first usually develop from
peripancreatic fluid accumulations that cause the pseudocysts formation in the setting of acute
pancreatitis. On the contrary, chronic pseudocysts develop as a result of ductal disruptions
[53]. Pseudocysts may be single or multiple, various in size. In fact, the pancreatic pseudocysts
generally are caused and long maintained by some leaks from the pancreatic ducts that give
the constant filling by pancreatic secretions [50]. A long history and clinical evolution of chronic
pancreatitis can give usually a clear diagnostic direction. Chronic recurrent abdominal pain
characterizes the clinical appearance of the disease. The other common symptoms are nausea
and vomiting, early satiety. Jaundice can occur in 10% of patients with a slow start due to bile
duct compression by the pseudocyst or the pancreatic flogosis. The imaging examinations,
particularly EUS, allow, beside the cystic lesion, to detect the characteristic parenchymal
features of chronic pancreatitis: the damage of the pancreatic duct system, parenchymal
fibrosis, and calcifications [53]. The Rosemont classification [58] of chronic pancreatitis, based
on EUS findings, identifies major criteria such as main pancreatic duct calculi and lobularity
and minor criteria with cysts, dilated ducts >3.5 mm, irregular pancreatic duct contour, and
dilated side branches >1 mm.
The surgical treatment of chronic pancreatitis should be based on the clinical and pathological
scenario: two types of surgical procedures with the aim of improving or eliminating ductal
hypertension by intestinal anastomotic drainage can be performed [53]. Resectional proce‐
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dures allow eliminating the areas of chronic inflammation frequently in the head of the
pancreas. A late complication of chronic pancreatitis encompasses evident ductal dilatation.
The incidence of these chronic pseudocysts is high: 20–40% [59]. The pseudocysts can be
connected with adjacent organs such as stomach or duodenum. Consequently, endoscopic
approach can be performed with mini‐invasive intent, cystogastrostomy, or duodenocystos‐
tomy [60]. The morbidity of this procedure is 3–11%, without mortality. The treatment of
chronic pseudocysts by drainage through the duodenal papilla and ductal system also has
been proposed by endoscopy. This procedure with ERCP allows putting in place the transpa‐
pillary endoprotesis as drainage. In addition, the transluminal stones removal and/or litho‐
tripsy can be possible, if intraductal stones are present [60–62]. The surgical management has
shown good results in the treatment of chronic pseudocysts, pancreatic duct dilatation with
stenosis, and stones. The Puestow procedure and its modifications of Partington and Rochelle
[63, 64] are the standard surgical drainage methods in chronic pancreatitis with pseudocyst
and/or dilated ducts. These interventions involve the anastomosis between dilated main duct
and pseudocystic wall with a Roux‐en‐Y loop of jejunum. The results show low morbidity
(<10%) and low mortality (<1%) with relief from abdominal pain in 85–90% of the patients [65–
67]. Sometimes, with a dilated pancreatic duct, a fibrotic inflammatory mass may be present
in the pancreas. In these cases, the interventions that couple drainage and resective procedures
defined “hybrid” can be chosen: Beger, Frey interventions, and some variants [67–69].
11. Indeterminate pancreatic cystic lesions
Cystic lesions of the pancreas today are an important diagnostic challenge. In each case the
specific diagnosis must be defined: pseudocysts, SCNs, MCNs, IPMNs, and SPPNs are the
most common lesions. Perhaps more important is to establish the malignant potential and the
objective data of a neoplastic degeneration. The diagnostic procedures to choose should be
geared toward minimally invasiveness. Imaging examinations are at the first line: CT, MRI,
MRCP, and PET are minimally invasive and have shown various degrees of sensitivity and
specificity. ERCP and EUS–FNA are invasive and can give some useful information. If imaging
findings allow the certain diagnosis of specific lesion of which is well known the malignant
potential and the characteristic features of malignant evolution, the therapeutic choices
(surgery or observation) are enough defined. Moreover, clinical symptomatic picture adds
further certainty to the treatment program. There are also, among cystic pancreatic neoplasms,
some well‐defined diagnoses characterized by imaging and clinical data for which the
management is uncertain and debatable. In summary, there are two problems in the manage‐
ment of cystic pancreatic lesions. Firstly, the difficulty in the diagnostic definition and/or in the
detection of malignancy; moreover, also, in some cases, the positive diagnosis of the lesions is
characterized by particular pathological and clinical features that cause uncertainty in the
choice of treatment between surgery, observation program, and for how many times the control
can be prolonged.
All clinical, pathological, and imaging findings with also analysis of cyst fluid examination by
EUS‐FNA have been reported above in the detailed report of each cystic lesions of the pancreas.
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This knowledge crucial for the diagnosis and management should be integrated by the
classification that separates pancreatic cystic lesions in two categories. There are pancreatic
cysts benign, not premalignant, such as SCNs, pseudocysts, lymphoepithelial cysts, and
lymphangioma, and pancreatic cysts premalignant and malignant such as MCNs, IPMNs,
SPPNs, and CPENs [70]. Roughly, the first conclusion can be the indication of surgical resection
for premalignant lesions and observation for benign or indolent lesions. The indeterminate
cystic lesions can be located between the cysts frankly benign such as pseudocysts or serous
cystadenoma or lymphangioma and, on the other hand, the cystic lesions frankly malignant
or with clear findings of malignant evolution such as MD‐IPMNs, IPMNs associated with
invasive carcinoma, MCNs with increased size, cyst‐wall irregularity, and intracystic solid
regions. In the indeterminate cystic lesions, the management choices can be debatable and
uncertain. In this group, small cysts with not certain diagnosis, small BD‐IPMNs, or MCNs
can be considered. Characteristic in this setting is the asymptomatic pancreatic cyst inciden‐
tally detected on abdominal CT. The improvement of an unclear diagnosis can be achieved
with MRI and MRCP. If the data obtained with these examinations are not conclusive (e.g.,
main duct <1 cm; thick cyst wall size >2 cm), the diagnostic process can continue with invasive
procedure such as EUS‐FNA. The detection of nodule or solid mass or main duct >1 cm and
cytology positive for malignancy is crucial for the surgical resection. In the patients without
these diagnostic data, the conservative option marked by periodic controls with CT or MRI or
EUS (repeat the control test in 6 months) can be evaluated [70]. In the patients with clear
diagnosis (CT, MRI, EUS, and clinical data), serous cystadenoma asymptomatic can be
followed with periodic imaging control with MRI or CT (repeat the control test in 1 year); if
symptomatic, overall in young patient (<65 years), surgery should be considered. Patients with
MD‐IPMNs, mixed‐type IPMNs, SPPNs, and MCNs should be proposed for surgical resection.
BD‐IPMNs characterized by main pancreatic duct >1 cm, cystic lesion in the head of pancreas,
jaundice, solid component, main duct with thickened wall, and mural nodule, which are
features concerning malignancy, can undergo surgical resection, if, without these findings, CT,
MRI, and EUS (repeat the control test in 6 months) may be followed conservatively.
There is almost unanimously consensus [32, 71] for surgical indications in patients with MCNs,
SPPNs, MD‐IPMNs, and mixed‐type IPMNs. Patients with serous cystadenoma should be
directed to conservative management. Surgery can be proposed only in symptomatic patients
or if the diagnosis is uncertain. Patients with BD‐IPMN can be observed also if the size lesion
is more than 3 cm unless there are features concerning for potential malignancy.
12. Clinical cases
This chapter can be completed with the presentation of some cases of cystic pancreatic
neoplasms treated in our Service. These detailed examinations can contribute to clarify several
clinical pathological features.
• First case study: female, 35 years old. Anamnestic data: non‐specific vague upper abdominal
pain and postprandial fullness since 4 months. The diagnosis is incidental by US and CT.
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The multislice CT shows cystic mass located in the tail of the pancreas, size 8.5 cm, uniloc‐
ular, fluid content, and wall well defined, with contact but not infiltration of posterior gastric
wall and splenic vessels. The cystic pancreatic lesion, with this radiologic features, may be
also a postnecrotic pseudocyst.
Differential diagnosis, for a cystic pancreatic lesion with these imaging features, may be
discussed between MCNs and postnecrotic pseudocysts (Figure 1).
Figure 1. MCN of the tail of the pancreas (arrow).
The first question is whether other examinations for preoperative diagnosis can be useful. In
these cases, the anamnestic data are most important: this patient had not in the past acute
pancreatitis that can explain pseudocyst. Consequently in our opinion, other abdominal
imaging cannot add other information. The preoperative diagnosis is MCN with the surgical
indication: distal pancreatectomy and splenectomy.
The second question regards the method of treatment of proximal pancreatic stump. The
transection (pancreatic body and splenic vein) with linear stapler and tubular drainage can be
suggested. The splenic artery is treated separately.
The third question regards the incidence of pancreatic fistula in distal pancreatectomy. The
most important and frequent complication of distal pancreatectomy is the pancreatic fistula.
The incidence of pancreatic fistula ranges from 5 to 30% [72–75]. This variability is explained
because there are no the standard definition of the fistula: there are a little gatherings or a few
drainage in the postoperative period that are not diagnosed as fistula. The criteria for grading
pancreatic fistula have been proposed by ISGPF [76, 77] based on drain and amylase level,
persistent drainage (>3 weeks), signs of infections, sepsis, clinical conditions, and need for
reoperation. The fistula can be classified, with increase of severity, as grades A, B, and C. The
grade A and B usually can be treated with non‐invasive approach: parenteral nutrition,
somatostatine, etc. CT control can be useful. Pathological feature shows cystic lesion, size 8.5 
cm, mucoid content with smooth surfaces, and thickened, glistening wall. Histological
diagnosis was mucinous cystadenoma. Lymph node is negative.
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The fourth question is whether surgical treatment with laparoscopic approach can be pro‐
posed. A laparoscopic approach is possible for small or medium size mucinous cystic tumors
located in the body or tail of the pancreas. The laparoscopic duodenopancreatectomy is a very
complex procedure not yet worldwide performed. But there are two important considerations:
not to break the cyst during the intervention because the spillage of mucoid material could
lead to tumor spread; moreover, the cyst should be removed intact because the pathologist can
do an appropriate examination of the complete wall of the cyst.
• Second case study: male, 80 years old. Anamnestic data: recurrent episodes of pancreatitis
with upper abdominal pain, hyperamilasemia, diabetes, mild alteration of cholestasis tests,
and no alcohol consumption since 10 months. The imaging examinations (US and CT) show
cystic lesions of the head of the pancreas, its size is 7 cm, mild dilation of main pancreatic
duct, and choledocal duct. The MRCP confirms the same lesion and no stones or sludge in
the bile duct (Figure 2).
Figure 2. MD‐IPMN of the head of pancreas (arrow).
Preoperative diagnosis: Because of previous episodes of acute pancreatitis and no biliary
stones and alcohol consumption, the proposed diagnosis may be cystic neoplasm. In addition,
in this case, we have had the pathognomonic sign: mucus extrusion through a bulging papilla
at endoscopy. The diagnosis was intraductal papillary mucinous neoplasm. There are clear
surgical indications: duodenpancreatectomy has been proposed.
Pathological description: head of the pancreas, increased in size (7.5 × 5.3 × 4.5 cm), and
dystrophic with cystic lesions with mucus. Histology: IPMN not invasive in the pancreatic
ductal ectasia with squamous metaplasia of epithelium. There is no neoplastic invasion in the
lymph nodes.
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In the surgical management, how to regulate the extension of pancreatic resection in IPMN is
very important. First consideration: IPMNs encompass a spectrum of epithelial changes from
adenoma to invasive adenocarcinoma; in addition, there is the propensity of the tumor to
spread microscopically along the pancreatic ducts. Because of these histopathological features,
the most simple therapeutic choice is the intraoperative control (by frozen section) to rule out
the presence of the tumor in the transection margin (over the all on main duct). In this
perspective, the extension of pancreatic resection is possible once or twice, but is corrected to
make a total pancreatectomy? The standard choices are difficult. In the experience of Massa‐
chusetts, General Hospital has performed 63% duodenopancreatectomy, 17% distal pancrea‐
tectomy, and 19% total pancreatectomy [28]. The positive frozen‐section intraoperative
examination ranges from 23 to 52%. If recurrence occurs in the pancreas after first intervention,
a second resection may be possible.
• Third case study: male, 78 years old. Anamnestic data: the patient has been operated for lung
cancer 3 years ago.
In the follow‐up, US of abdomen shows cystic lesion of the pancreatic head. As the most
patients with serous cystadenoma, our patient was asymptomatic and the diagnosis incidental.
CT and MRI confirm cystic tumor (size 1.5 cm) in the head of pancreas, well circumscribed and
multinodular. There are also mild dilation of main bile duct and Wirsung. Our conclusion was
for SCN (Figure 3).
Figure 3. SCN of the head of the pancreas (arrow).
In this patient, the diagnosis may be serous cystadenoma and the therapeutic choice is the
organized controls. At present, we have made three controls (by imaging) every 6 months:
There is no clinical or morphological modification of the lesion.
The first question is in which patients, the prolonged observation of the cystic tumor of the
pancreas may be reasonable? Serous cystadenomas are indolent, slow‐growing tumors, with
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a very low incidence of malignancy (3%) [17]. These lesions become symptomatic with the
increase in size. The reasonable therapeutic organization for serous tumors may be the
following: first to take the certainty of the clinical diagnosis (serous cystic neoplasm).
Patient with little lesion (<4 cm) asymptomatic (in addition take in mind the great incidence of
this tumors in sixth–seventh decade) with certain diagnosis can be undergone to non‐operative
treatment and followed up. Patient with the lesion bigger in size (>4 cm) symptomatic, in
particular if younger, may be undergone to surgical treatment with pancreatic resection.
13. Conclusions
The improvement of imaging, endoscopic modalities, and cyst fluid studies allow now
accurate and reliable diagnosis of pancreatic cystic lesions.
Moreover, the enlarged knowledge of valuable pathological studies established the potential
for malignant transformation of these lesions identifying higher‐risk lesions. Finally, the
management options should be based on the assessment of each type of cystic neoplasms and
the distinction of pancreatic cystic neoplasms from other pancreatic cystic lesions.
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